Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SRPT stock price vs AMAT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMAT's multiple
Needs AMAT P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · AMAT FY 2025 (ended Oct 26, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
APPLIED MATERIALS INC /DE · implied price per share
Bear
$93.60
Base
$110.12
Bull
$126.64
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
0.32x
Net debt / EBITDA
Leverage against operating earnings
0.01x
-0.20x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$8.57B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
LAM RESEARCH CORP
SRPT vs LRCX
ASML HOLDING NV
SRPT vs ASML
TERADYNE, INC
SRPT vs TER
MKS INSTRUMENTS INC
SRPT vs MKSI
KLA CORP
SRPT vs KLAC
SKYWORKS SOLUTIONS, INC.
SRPT vs SWKS
$934.46M
$6.56B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can materially improve margins and move toward sustained profitability, then the current price is more defensible; otherwise, avoid chasing AMAT-implied upside because the valuation gap is driven by AMAT’s much stronger earnings power and quality profile.
SRPT’s current price of $19.28 is far below AMAT-implied value of $353.38, but that gap is driven by using AMAT’s much richer sales multiple rather than comparable business economics. SRPT’s own historical band of $17.35 to $21.21 shows the stock is trading near its recent range, suggesting the market is not validating AMAT-based upside.
Supporting Metrics
